TTT-26's Management Targets for Fiscal 2026
First written in FY2025. 2 of 3 entries say "Restated". Latest entry: FY2026.
No other company in this theme has enough history to compare yet.
- FY2026RestatedAnnual report
「We aim to achieve FY2026 management targets of ¥101.0 billion in net sales, ¥14.6 billion in operating profit, ROE of at least 25% and ROIC of at least 22%.」
The company continues to target TTT-26 management goals for FY2026 of ¥101.0 billion in net sales, ¥14.6 billion in operating profit, ROE of at least 25% and ROIC of at least 22%. - FY2026-H1RestatedAnnual report
「Against this backdrop, our group has pursued initiatives to increase corporate value and achieve the medium-term management plan Together Toward Transformation 26 (TTT-26), formulated in November 2023, focusing on ① improving profitability, ② improving capital efficiency, ③ optimizing finances and returning profits to shareholders, and ④ creating social value. We have strengthened our approach to the semiconductor and pharmaceutical industries and reformed our engineering processes to improve productivity and profitability, while implementing various initiatives to achieve sustainability management.」
There have been no material changes to the name of the TTT-26 plan, its 4 priority areas or its key initiatives. The company continues to strengthen sales to the semiconductor and pharmaceutical industries, reform its engineering processes, improve productivity and profitability, and pursue sustainability management. - FY2025First statedAnnual report
「We aim to achieve FY2026 management targets of ¥101.0 billion in net sales, ¥14.6 billion in operating profit, ROE of at least 25% and ROIC of at least 22%.」
TTT-26 set out for the first time management targets through FY2026 of ¥101.0 billion in net sales, ¥14.6 billion in operating profit, ROE of at least 25% and ROIC of at least 22%.